Research has shown that drugs can alleviate cisplatin-induced renal tubular cell apoptosis by reducing the levels of cleaved Caspase-3 and cleaved PARP, as well as the Bax/Bcl-2 ratio (Zhang J. et al., 2023); inhibiting NF-κB-mediated activation of the NLRP3/Caspase-1/GSDMD pathway to alleviate cisplatin-induced renal tubular cell pyroptosis (Jiang et al., 2021); and inhibiting RIP1/RIP3/MLKL-mediated programmed necroptosis (Wu et al., 2020), thereby suppressing CI-AKI. Here, RIPK3 is linked to acute kidney injury.